The shadow of generic competition has consistently loomed above copyright’s iconic drug, Viagra, raising questions about the prospects of connected pharmaceutical holdings. While initial times saw impressive returns, the exclusivity lapse has allowed the path for discounted substitutes, potentially diminishing revenue and creating a genuine dange